Company profile: Latigo Bio
1.1 - Company Overview
Company description
- Provider of clinical-stage, non-opioid therapies for chronic pain, including LTGO-33, a selective NaV1.8 inhibitor, and a Nav1.8 pain program. Leverages ion channel expertise, human tissue and genetic data, a proprietary discovery engine, and multiparameter optimization to identify, validate, and optimize small-molecule candidates targeting pain-related channels.
Products and services
- Nav1.8 Pain Program: Architects non-opioid therapies by targeting the human-validated NaV1.8 sodium channel, advancing drug candidates that inhibit pain signaling at a target validated as a human pain target
- LTGO-33: An isoform-selective small molecule inhibitor of voltage-gated NaV1.8 that suppresses pain signals while sparing other NaV isoforms to maintain specificity and non-opioid mechanism
- Discovery Engine: A proprietary platform integrating sophisticated models with human tissue and genetic insights to discover novel pain therapies and inform target selection for pain-related ion channels
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Latigo Bio
Synaptive Medical
HQ: Canada
Website
- Description: Provider of neurosurgery, medical imaging and surgical navigation solutions, including the Synaptive Integrated Suite to integrate information and automation across interventions; Modus X robotic exoscope with 4K 3D and fluorescence visualization; Modus Plan automatic tractography segmentation; Modus Nav instrument tracking via intraoperative tractography; Synaptive MRI point-of-care MRI; ImageDrive zero-footprint HTML5 viewer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Synaptive Medical company profile →
SafeOp Surgical
HQ: United States
Website
- Description: Provider of a neuromonitoring device to prevent nerve damage in all types of surgical procedures, founded in 2011 and headquartered in Hunt Valley, Maryland.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full SafeOp Surgical company profile →
Inscopix
HQ: United States
Website
- Description: Provider of neural activity imaging solutions for freely behaving subjects, enabling links between circuit dynamics and behavior. Offers the nVue dual-color system with expanded storage for longitudinal studies, the LScape module for wider field of view and longer working distance in cortical imaging, and Multicolor Data Processing software for streamlined miniscope analysis with PCA/ICA or CNMFe, filtering, and longitudinal registration.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Inscopix company profile →
NeuroReality
HQ: The Netherlands
Website
- Description: Provider of VR-based cognitive rehabilitation and brain training solutions using neuroscience and gamification. Offers Koji's Quest, a patient-centric SaaS VR game for recovery from brain injuries, connecting clinicians and patients to improve outcomes and enable superior care. Organizes clinical trials to evaluate effectiveness and prepares Koji's Quest for individual self-training via the Oculus Quest store.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NeuroReality company profile →
SwanBio Therapeutics
HQ: United States
Website
- Description: Provider of gene therapy focused on genetically defined therapies for neurological disorders. Offerings include SBT101, a candidate for adrenomyeloneuropathy targeting ABCD1 via AAV9; pipeline development in spinal cord-related indications; clinical trials, including a Phase 1/2 study of SBT101 and natural history studies of AMN; and patient and family resources, including trial information and compassionate use policies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full SwanBio Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Latigo Bio
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Latigo Bio
2.2 - Growth funds investing in similar companies to Latigo Bio
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Latigo Bio
4.2 - Public trading comparable groups for Latigo Bio
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →